Protagonist Therapeutics, Inc.

PTGX

US74366E1029

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-07-02 pm EDT			Pre-market 09:26:17 am
34.59 ^USD	-1.73%		34.62	+0.10%

12:00am	Protagonist Therapeutics, Inc.(NasdaqGM:PTGX) added to S&P 1000	CI
12:00am	Protagonist Therapeutics, Inc.(NasdaqGM:PTGX) added to S&P 600 Health Care	CI

Protagonist Therapeutics, Inc.(NasdaqGM:PTGX) added to S&P 1000

July 02, 2024

Latest news about Protagonist Therapeutics, Inc.

Protagonist Therapeutics, Inc.(NasdaqGM:PTGX) added to S&P 1000	2024-07-02	CI
Protagonist Therapeutics, Inc.(NasdaqGM:PTGX) added to S&P 600 Health Care	2024-07-02	CI
Protagonist Therapeutics, Inc.(NasdaqGM:PTGX) added to S&P Composite 1500	2024-07-02	CI
Protagonist Therapeutics, Inc.(NasdaqGM:PTGX) added to S&P 600	2024-07-02	CI
Protagonist Therapeutics, Inc.(NasdaqGM:PTGX) dropped from Russell 3000E Value Index	Jun. 30	CI
Protagonist Therapeutics to Join S&P SmallCap 600	Jun. 28	MT
Protagonist Therapeutics, Inc. Reports Updated Long Term Results from Rusfertide Phase 2 REVIVE Study at the EHA2024 Congress Showowing Durable Hematocrit Control	Jun. 14	CI
Protagonist Therapeutics Insider Sold Shares Worth $1,231,650, According to a Recent SEC Filing	Jun. 11	MT
Protagonist Therapeutics Insider Sold Shares Worth $280,000, According to a Recent SEC Filing	Jun. 11	MT
Protagonist Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 07	CI
Protagonist Therapeutics Insider Sold Shares Worth $707,750, According to a Recent SEC Filing	Apr. 03	MT
Protagonist Therapeutics, Inc. Provides Update on Verify Patient Enrollment and Timing of Top-Line Data	Mar. 26	CI
Protagonist Therapeutics Announces Closing of Worldwide Rusfertide License and Collaboration Agreement with Takeda	Mar. 18	CI
Protagonist Therapeutics' Potential Plaque Psoriasis Drug Shows High Skin Clearance Rates in Phase 2B Study	Mar. 11	MT
Protagonist Therapeutics, Inc. Announces Late-Breaking Presentation At the American Academy of Dermatology 2024 Annual Meeting with Positive Results from the Phase 2B Frontier 2 Long-Term Extension Study Evaluating JNJ-2113, the First and Only Investigational Targeted Oral Peptide Designed to Block the IL-23 Receptor, for Adult Patients with Moderate-To-Severe Plaque Psoriasis	Mar. 11	CI
Protagonist Therapeutics Insider Sold Shares Worth $948,600, According to a Recent SEC Filing	Mar. 04	MT
Protagonist Therapeutics Insider Sold Shares Worth $406,637, According to a Recent SEC Filing	Mar. 04	MT
Protagonist Therapeutics Insider Sold Shares Worth $764,365, According to a Recent SEC Filing	Mar. 04	MT
JPMorgan Adjusts Price Target on Protagonist Therapeutics to $37 From $34, Maintains Overweight Rating	Feb. 28	MT
Protagonist Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 27	CI
Protagonist Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 27	CI
Protagonist Therapeutics Shares Rise 5.6% on Licensing Deal With Takeda	Jan. 31	DJ
Transcript : Protagonist Therapeutics, Inc. - Special Call	Jan. 31
Takeda and Protagonist Therapeutics, Inc. Enter into Worldwide License and Collaboration Agreement for Rusfertide, a Late-Stage Rare Hematology Asset	Jan. 31	CI
Transcript : Protagonist Therapeutics, Inc. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-09-2024 09:45 AM	Jan. 09

Chart Protagonist Therapeutics, Inc.

Duration

Period

More charts

Protagonist Therapeutics, Inc. is a biopharmaceutical company. The Company uses its peptide-based chemical entities rusfertide and JNJ-2113 in different stages of development, all derived from its proprietary discovery technology platform. The Companyâs clinical programs fall into two categories of diseases: hematology and blood disorders, and inflammatory and immunomodulatory diseases. Its lead clinical asset, rusfertide (PTG-300), is an injectable hepcidin mimetic in development for the potential treatment of polycythemia vera (PV) and other blood disorders. The Companyâs Interleukin-23 receptor (IL-23R) antagonist compound JNJ-2113 is an orally delivered investigational drug that is designed to block biological pathways targeted by marketed injectable antibody drugs. Its PN-943 is a wholly owned investigational orally delivered gut-restricted alpha 4 beta 7 (Î±4Î²7) specific integrin antagonist for inflammatory bowel disease (IBD).

Sector

Biotechnology & Medical Research

Calendar

2024-07-31 - Q2 2024 Earnings Release (Projected)

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for Protagonist Therapeutics, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

34.59 USD

Average target price

43.83 USD

Spread / Average Target

+26.72%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
PROTAGONIST THERAPEUTICS, INC.	+50.85%	2.03B
MODERNA, INC.	+17.72%	44.87B
IQVIA HOLDINGS INC.	-10.33%	37.8B
LONZA GROUP AG	+40.94%	37.61B
ALNYLAM PHARMACEUTICALS, INC.	+29.36%	31.32B
CELLTRION, INC.	-8.44%	27.4B
ICON PUBLIC LIMITED COMPANY	+12.45%	26.32B
UNITED THERAPEUTICS CORPORATION	+44.19%	14.07B
MEDPACE HOLDINGS, INC.	+31.93%	12.5B
BIO-TECHNE CORPORATION	-7.67%	11.23B

Other Biotechnology & Medical Research